Dr Reddy’s Laboratories: Global pharmaceutical company, India
Global pharmaceutical and drug development company from India, 

operating in over 100 countries worldwide.
  Quick Links
   Company News Coverage
   Sustainability Report
   NCE Pipeline
   Our Values
 
 
Dr. Reddy's
               in the news
  Press Coverage
Subscriptions: Want to stay updated? Click here to subscribe to our press releases
 
     
 


Money Today
December 27, 2007

From Babu to Corporate Honcho

Career as Asset - Case Studies of successful career switches
Prabir Jha's career focus did not waver nor did his professional plans go awry after quitting his cushy government job.

Click Here for the complete Story
[PDF Format]
 
     
 


Business India

December 16, 2007

Betting on biotech

Dr. Reddy's is concentrating now on biotechnology-based products and going for acquisitions to provide a base for launching them

Click Here for the complete Story
[PDF Format]
 
     
 


PharmaTech.com

September 2, 2007

Leading the Pack - Lessons learned from the Top

Life isn't so relaxing at the top. Ranking first among Indian pharmaceutical companies, Dr. Reddy's Laboratories (Hyderabad) is in itself a model that a lot of companies in the Indian industry have either drawn inspiration from or at best imitated.

Click Here for the complete Story
[HTML Format]
 
     
 


Business Today

November 18, 2007

The Best Companies to work for in India

A BT-Mercer-TNS survey of India's best employers

Click Here for the complete Story
[PDF Format]
 
     
 


Los Angeles Times

June 9, 2007

Latin America attracting investors from India

Similarities in consumer bases help make the region a natural market.

Ask for directions to Dr. Reddy's Laboratories Ltd. in this industrial city in central Mexico and locals will give you a curious look.Many are unfamiliar with the drug maker, one of India's largest pharmaceutical companies, which purchased a production facility here in late 2005 for about $59 million.

It may be the first time they've heard of an Indian company doing business in Mexico, but it won't be the last.

Click Here for the complete Story
[HTML Format]
 
     
 


Rediff News
June 12, 2007

Dr Reddy's: From Rs 25 lakh to Rs 5,800 crore

The Patents Act signalled the arrival of good times for the pharmaceutical companies. Soon after the Act was announced, hundreds of companies started reverse engineering of western pharmaceutical products. There was a virtual explosion in the pharma space, with entrepreneurs making most of this opportunity.

Click Here for the complete Story
[HTML Format]
 
     
 


Outlook - Business

May 5, 2007

Globe, A Place For You and Me

Building global firms may not always be a stuff of fairy tales. Stick to a few basic principles, most often, you're there. Dr. Reddy's has a story for corporations looking for an international footprint.

GV Prasad Vice Chairman &CEO, Dr. Reddy's Laboratories

Click Here for the complete Story
[PDF Format]
 
     
 


Newsweek International

March 2007

Foe Turned Friend

Indian generic-drug makers once bedeviled Big Pharma; now they may be its best hope for success.

Click Here for the complete Story
[HTML Format]
 
     


Modern Pharmaceuticals

February - March 2007

Leaders Speak Dr. K. Anji Reddy.

"Building a global generic business and increasing geographical expansion are key priorities for us"

Click Here for the complete Story
[PDF Format]
 
     


Bloomberg Markets

January 2007

Dr. Reddy's Pfizer Fixation

Special feature on Dr. Reddy's Labs

India's maker of generic Prozac and Cipro, stung by flops and failed patent challenges, is staking its future on its founder's quest to create a homegrown blockbuster drug.

Click Here for the complete Story
[PDF Format]
 
   
  Triple Bottom Line
Triple bottom line
Billion Dollars turnover movie
  Download Brochures
Download brochures of Dr. Reddy's
  Key Milestones
Key milestones of Dr. Reddy's
Designed by Bodhtree SOA Consulting Company
© 2001 - 2008 Dr. Reddy's Laboratories Ltd. All rights reserved
Site best viewed at 800x600 resolution